Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Reliq Health Technologies Inc V.RHT.H

Alternate Symbol(s):  RQHTF

Reliq Health Technologies Inc. is a global healthcare technology company that specializes in developing virtual care solutions for the healthcare market. The Company’s iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent hospital readmissions and ER visits. The iUGO Care platform integrates wearables, sensors, voice technology and mobile apps and desktop user interfaces for patients, clinicians and healthcare administrators. The iUGO Care platform provides services, such as remote patient monitoring, chronic care management, principal care management, behavioral health integration, telemedicine, transitional care management, wound care, and others.


TSXV:RHT.H - Post by User

Post by theinvestor22on May 30, 2023 11:12pm
241 Views
Post# 35471599

fQ3 results

fQ3 resultsRevenue was up, although the SaaS increase could have been higher.  Regardless, device revenue leads to SaaS revenue, so I'll take it.  Gross margin was nicely up and progressing well toward their target level.  Expenses continue to be well controlled.  Of note is R&D expense, which had been higher than normal for several quarters, but is now starting to return to normal levels because they are nearing completion of the one-time FHIR implementation work.  Bottom line - they make a profit of $731,017, which is a solid first. 

The continuing issue of delayed collections is still there.  I didn't expect much out of fQ3 on that front because collections traction only started in earnest late in fQ3.  I would expect, however, a status report tomorrow in the NR and/or the webinar.

Overall, kudos to Reliq.  They're getting closer to being de-risked...
<< Previous
Bullboard Posts
Next >>